BioCentury | Apr 1, 2020
Product Development

The Race Is On: Strategies for COVID-19 Product Development

Industry leaders and policy advisers on the front lines of the fight against COVID-19 in the U.S. and China joined BioCentury on March 31 for a webinar about the race to develop medical countermeasures. The...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 19, 2020
Product Development

Slotting anti-inflammatories into COVID-19 treatment

While repurposed agents for COVID-19 have largely focused on suppressing SARS-CoV-2, there is a strong case to be made for evaluating anti-inflammatory agents in patients with severe disease. As more emerges about the disease, it’s...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

Fudan University develops pan-coronavirus inhibitor   A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

Eleven COVID-19 patients discharged after receiving Ascletis drug  Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19 patients in a cohort receiving Ganovo danoprevir plus ritonavir in a Chinese Phase IV trial have been discharged from...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, bringing the total number of trials testing the...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for activity...
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BioCentury | Feb 4, 2020
Product Development

The Coronavirus outbreak: Letter from the Editor

The outbreak of the Coronavirus 2019-nCoV has caused us all to stop in our tracks, take stock of what we’re doing and what we should be doing, and reassess the plans we set out for...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
Items per page:
1 - 10 of 147
BioCentury | Apr 1, 2020
Product Development

The Race Is On: Strategies for COVID-19 Product Development

Industry leaders and policy advisers on the front lines of the fight against COVID-19 in the U.S. and China joined BioCentury on March 31 for a webinar about the race to develop medical countermeasures. The...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced on Wednesday a partnership with the U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their...
BioCentury | Mar 19, 2020
Product Development

Slotting anti-inflammatories into COVID-19 treatment

While repurposed agents for COVID-19 have largely focused on suppressing SARS-CoV-2, there is a strong case to be made for evaluating anti-inflammatory agents in patients with severe disease. As more emerges about the disease, it’s...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

Fudan University develops pan-coronavirus inhibitor   A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

Eleven COVID-19 patients discharged after receiving Ascletis drug  Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19 patients in a cohort receiving Ganovo danoprevir plus ritonavir in a Chinese Phase IV trial have been discharged from...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, bringing the total number of trials testing the...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for activity...
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BioCentury | Feb 4, 2020
Product Development

The Coronavirus outbreak: Letter from the Editor

The outbreak of the Coronavirus 2019-nCoV has caused us all to stop in our tracks, take stock of what we’re doing and what we should be doing, and reassess the plans we set out for...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
Items per page:
1 - 10 of 147